Drug Discovery World

DECEMBER 29, 2022

Recombinant DNA technology and its impact on modern drug discovery . Sitting Down With . Catch up on the Sitting Down With podcast episodes released in 2022: . How to accelerate mouse model generation without reducing quality . Exploring the microbiome: how it is shaping preclinical research . Narrated Podcasts.

Recombinant DNA Technology 52

Recombinant DNA Technology Genome Genomics DNA 52

Advarra

JUNE 13, 2024

Recombinant DNA technologies and genetically modified biological agents are being adapted for a wide scope of therapeutic applications, and their use is becoming increasingly common in clinical trials.

Genetic Engineering 52

Genetic Engineering Clinical Trials Clinical Trials Engineer 52

Cloudbyz

MARCH 6, 2024

Unlike traditional small molecule drugs, which are chemically synthesized, biologics are produced through complex biotechnological processes, often involving recombinant DNA technology. Understanding Biologics: Biologics are a class of therapeutic agents derived from living organisms, such as cells, tissues, or proteins.

Gene 99

Gene Immune Response Manufacturing Gene Therapy 99

Pharmaceutical Technology

FEBRUARY 15, 2023

Innovation S-curve for the pharmaceutical industry Gene splicing using nucleases is a key innovation area in the pharmaceutical industry Nucleases play a fundamental role in the field of recombinant DNA technology, or genetic engineering. Nucleases are enzymes that hydrolytically cleave the phosphodiester backbone of DNA.

Gene Splicing 130

Gene Splicing Gene Recombinant DNA Technology DNA 130

pharmaphorum

FEBRUARY 22, 2021

Sanofi’s shot combines the recombinant DNA technology it uses to make flue vaccines with the adjuvants GSK uses to boost the immune system with its jabs. A single shot vaccine from Johnson & Johnson is also being reviewed by the FDA, which could also be approved in Europe in the coming weeks.

Vaccination 89

Vaccination Vaccine Recombinant DNA Technology Trials 89

The Pharma Data

JULY 11, 2021

TAKHZYRO is produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology. TAKHZYRO is a fully human monoclonal antibody that specifically binds and decreases plasma kallikrein activity. TAKHZYRO is formulated for subcutaneous administration and has a half-life of approximately two weeks in patients with HAE.

Allergies 52

Allergies Antibody Recombinant DNA Technology Production 52

Drug Discovery World

MAY 4, 2023

Recombinant DNA technology and improved protein purification techniques further contributed to our understanding and explorations of drug targets. For instance, most successful drug targets were proteases and G-protein coupled receptors with definite characteristics.

Medicine 52

Medicine Protein Drugs Bioassay 52